Home » Stocks » ORTX

Orchard Therapeutics PLC (ORTX)

Stock Price: $3.06 USD -0.12 (-3.77%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
After-hours: $3.18 +0.12 (3.92%) Jul 23, 7:34 PM
Market Cap 378.73M
Revenue (ttm) 2.60M
Net Income (ttm) -136.59M
Shares Out 123.77M
EPS (ttm) -1.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $3.06
Previous Close $3.18
Change ($) -0.12
Change (%) -3.77%
Day's Open 3.18
Day's Range 3.04 - 3.25
Day's Volume 653,408
52-Week Range 3.04 - 9.08

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Orchard Therapeutics plc (NASDAQ: ORTX) and Pharming Group NV (NASDAQ: PHAR) have collaborated to research, develop, manufacture and commercialize OTL-105 for hereditary angioedema (HAE). OTL-105 is an ...

3 weeks ago - Benzinga

Highlights the broader potential of Orchard's ex vivo HSC gene therapy platform approach in new and larger indications

3 weeks ago - GlobeNewsWire

Orchard Therapeutics plc (NASDAQ: ORTX) has provided updates on the progress of its lead gene therapy programs targeting metachromatic leukodystrophy (MLD), mucopolysaccharidosis type I Hurler syndrome ...

3 weeks ago - Benzinga

Expected clinical package for OTL-200 BLA for MLD using data from existing patients clarified with FDA

3 weeks ago - GlobeNewsWire

Commercial Activities Advancing for Upcoming Launch of Libmeldy TM (atidarsagene autotemcel) for Eligible Patients with Early-onset MLD in Germany

2 months ago - GlobeNewsWire

Three years after receiving gene therapy from Orchard Therapeutics (NASDAQ: ORTX) in an early-stage clinical trial, 100% of patients with an inherited disease that damages the immune system were still a...

2 months ago - Benzinga

100% overall survival and ≥ 95% event-free survival observed at two and three years following one-time treatment with lentiviral HSC gene therapy

2 months ago - GlobeNewsWire

Seven abstracts accepted show the potential of HSC gene therapy to transform the treatment of multiple severe rare disorders

2 months ago - GlobeNewsWire

Cell and gene therapy companies are quickly emerging as favorites of venture capital firms, investors and members of Big Pharma, according to a report from the Alliance for Regenerative Medicine.

Other stocks mentioned: BIIB, FATE, GILD, JNJ, SANA, SGMO
4 months ago - GuruFocus

With all due respect to Elton John, the real Rocket Man is in Cranbury, New Jersey.

Other stocks mentioned: AVRO, BLUE, BOLD, QURE, RCKT, SRPT
4 months ago - GuruFocus

MINNEAPOLIS--(BUSINESS WIRE)--Be The Match BioTherapies announced an expansion of their multi-year partnership with Orchard Therapeutics.

4 months ago - Business Wire

Shares of Orchard Therapeutics (NASDAQ:ORTX) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share were up 26.09% year over year to ($0.34), which beat the esti...

4 months ago - Benzinga

$150M Strategic Financing Supports Execution into the First Half of 2023

4 months ago - GlobeNewsWire

BOSTON and LONDON, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present at the following ...

4 months ago - GlobeNewsWire

Orchard Therapeutics (ORTX) will provide updates on earnings, revenues of Strimvelis and the pipeline when it releases results for fourth-quarter 2020.

5 months ago - Zacks Investment Research

The company released some promising data from a pair of proof-of-concept studies.

5 months ago - The Motley Fool

Orchard Therapeutics Plc (NASDAQ: ORTX) gains in premarket in reaction to positive interim data from a proof-of-concept study evaluating its gene therapy OTL-203 in Mucopolysaccharidosis type I (MPS-I)....

5 months ago - Benzinga

All eight patients treated with OTL-203 show stable cognitive function, motor function and growth within the normal range at multiple data points post-treatment

5 months ago - GlobeNewsWire

Infinity Pharmaceuticals (NASDAQ: INFI) shares are trading higher Friday after JPMorgan upgraded the stock from Underweight to Neutral. Infinity Pharmaceuticals is a clinical-stage biopharmaceutical com...

Other stocks mentioned: BCLI, INFI, VIVO
5 months ago - Benzinga

Strengthened Financial Position Supports Execution into the First Half of 2023 Strengthened Financial Position Supports Execution into the First Half of 2023

5 months ago - GlobeNewsWire

Commercial Launch of Libmeldy™ in Europe On-Track for 1H 2021 Commercial Launch of Libmeldy™ in Europe On-Track for 1H 2021

5 months ago - GlobeNewsWire

Nine abstracts accepted demonstrating potential of HSC gene therapy to treat multiple neurodegenerative disorders

5 months ago - GlobeNewsWire

BOSTON and LONDON, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced plans to extend the company's commercial reach in the Middle East ...

6 months ago - GlobeNewsWire

The FDA bestows a Regenerative Medicine Advanced Therapy status on Orchard Therapeutics' (ORTX) investigational gene therapy, OTL-200, for treating early-onset metachromatic leukodystrophy. Shares up.

6 months ago - Zacks Investment Research

Orchard Therapeutics (ORTX) stock is on the rise Wednesday with heavy trading even with there being no major news about the company. The post ORTX Stock Alert: 8 Things to Know About Gene Therapy Play O...

6 months ago - InvestorPlace

BOSTON and LONDON, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the 39th Annual J.P. M...

6 months ago - GlobeNewsWire

First gene therapy to receive full EU marketing authorization for eligible MLD patients

7 months ago - GlobeNewsWire

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Other stocks mentioned: AUDC, BLCM, INUV
7 months ago - Zacks Investment Research

Preliminary results from first patient treated with OTL-201 show over expression of the therapeutic enzyme and decrease in substrate levels three months following gene therapy Preliminary results from f...

7 months ago - GlobeNewsWire

BOSTON and LONDON, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that its chief executive officer, Bobby Gaspar, M.D., Ph.D. will p...

8 months ago - GlobeNewsWire

BOSTON and LONDON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the U.S. Food and Drug Administration (FDA) has cleared the c...

8 months ago - GlobeNewsWire

These companies are devoted to helping patients who don't have any other options.

Other stocks mentioned: ALXN
8 months ago - The Motley Fool

BOSTON and LONDON, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the Barclays Gene Edit...

8 months ago - GlobeNewsWire

Preliminary results from first patient in ongoing proof-of-concept trial show evidence of engraftment of gene-modified cells three months following treatment Preliminary results from first patient in on...

8 months ago - GlobeNewsWire

Orchard just received a positive node from CHMP for its lead drug candidate. US approval should be next.

8 months ago - Seeking Alpha

BOSTON and LONDON, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will webcast a virtual R&D event ‘New Horizons in...

8 months ago - GlobeNewsWire

BOSTON and LONDON, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company's chief executive officer, Bobby Gaspar, M.D., Ph...

9 months ago - GlobeNewsWire

First therapy recommended for full marketing authorization in the EU for eligible patients with confirmed diagnosis of late infantile or early juvenile MLD variants

9 months ago - GlobeNewsWire

BOSTON and LONDON, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the European Medicines Agency (EMA) has granted Priority M...

9 months ago - GlobeNewsWire

BOSTON and LONDON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the following virtu...

10 months ago - GlobeNewsWire

Data on all eight patients demonstrate sustained engraftment and supranormal IDUA enzyme expression

10 months ago - GlobeNewsWire

No news is good news for this biotech company.

10 months ago - The Motley Fool

BOSTON and LONDON, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced presentations at the upcoming 46th Annual Meeting of the Europea...

11 months ago - GlobeNewsWire

Orchard Therapeutics plc (ORTX) CEO Bobby Gaspar on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

BOSTON and LONDON, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the Wedbush PacGrow ...

11 months ago - GlobeNewsWire

Orchard Therapeutics: An Undervalued Gene Therapy Company

1 year ago - Seeking Alpha

BOSTON and LONDON, July 20, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company has received both orphan drug designation and r...

1 year ago - GlobeNewsWire

BOSTON and LONDON, July 15, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company has entered into two worldwide royalty-bearing ...

1 year ago - GlobeNewsWire

BOSTON and LONDON and MILAN, Italy, July 09, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, and MolMed S.p.A (MLMD.MI), one of the company’s principal cont...

1 year ago - GlobeNewsWire

BOSTON and LONDON, May 27, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that presentations by the management team will be made at the fol...

1 year ago - GlobeNewsWire

About ORTX

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinica... [Read more...]

Industry
Biotechnology
IPO Date
Oct 31, 2018
Stock Exchange
NASDAQ
Ticker Symbol
ORTX
Full Company Profile

Financial Performance

In 2020, ORTX's revenue was $2.60 million, an increase of 3.26% compared to the previous year's $2.51 million. Losses were -$151.98 million, -7.00% less than in 2019.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for ORTX stock is "Strong Buy." The 12-month stock price forecast is 13.10, which is an increase of 328.10% from the latest price.

Price Target
$13.10
(328.10% upside)
Analyst Consensus: Strong Buy